Volume 4, Issue 1 (Spring & Summer 2020)                   J Res Urol 2020, 4(1): 1-9 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohseni M, Ariania R. Comparison of PSA profile with positive prostate cancer pathology and Gleason scores in 2015-2017 in Hamadan. J Res Urol 2020; 4 (1) :1-9
URL: http://urology.umsha.ac.ir/article-1-75-en.html
1- Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran , mao.mohseni@gmail.com
2- Urology Department, Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract:   (5768 Views)
Background and Objective: Prostate cancer is one of the most common cancers of the urinary system. The most used method for diagnosis is transrectal ultrasonography-guided biopsy. The purpose of this study is a statistical analysis with the aim of reducing unnecessary biopsies based on individual, geographical and genetic patterns in our region.
Methods: The medical records of all patients who underwent prostate biopsy in Shahid Beheshti Hospital, Hamadan, Iran, during 2015-2017 were reviewed and the data obtained from their study were evaluated by the researcher.
Results: Of patients 72.4% had total prostate-specific antigen (PSA) equal to or greater than 10 ng/mL. the majority of patients had benign prostatic hyperplasia (67.4%). Most of the patients had PSAD and F / T above 15% (61.3%) and 18% (52.3%), respectively. By the increasing of total PSA, the percentage of people with prostate cancer increased, and there was a significant relationship between total PSA and the presence of prostate cancer. But for PSAD and F/T there was no significant relationship with prostate cancer. The minimum total PSA in the prostate cancer group was 5.40.
Conclusion: In order to reduce unnecessary biopsies and related complications as well as stress imposed on the patient and his family, in this geographical area, we may be able to avoid biopsy in PSA level below 5/4, especially in older ages with normal physical examination and no risk factor. Certainly, to achieve a practical regional guideline, we will need more comprehensive and prospective studies in future.
Full-Text [PDF 466 kb]   (1571 Downloads)    
Type of Study: Research | Subject: Urologic oncology
Received: 2020/06/10 | Accepted: 2020/09/12 | Published: 2020/09/18

References
1. Brawley OW. Prostate cancer epidemiology in the United States. World journal of urology. 2012 Apr 1;30(2):195-200. [DOI:10.1007/s00345-012-0824-2] [PMID]
2. Catalona WJ, Richie JP, Ahmann FR, Hudson ML, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. The Journal of urology. 1994 May;151(5):1283-90. [DOI:10.1016/S0022-5347(17)35233-3]
3. Chen N, Zhou Q. The evolving Gleason grading system. Chinese Journal of Cancer Research. 2016 Feb;28(1):58.
4. Eastham J. Prostate cancer screening. Investigative and Clinical Urology. 2017;58(4):217-9. [DOI:10.4111/icu.2017.58.4.217] [PMID] [PMCID]
5. McDougal WS, Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh Urology 11th Edition Review E-Book. Elsevier Health Sciences; 2015 Sep 25.
6. Chen R, Huang Y, Cai X, Xie L, He D, Zhou L, Xu C, Gao X, Ren S, Wang F, Ma L. Age-specific cutoff value for the application of percent free prostate-specific antigen (PSA) in Chinese men with serum PSA levels of 4.0-10.0 ng/ml. PloS one. 2015 Jun 19;10(6):e0130308. [DOI:10.1371/journal.pone.0130308] [PMID] [PMCID]
7. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. Jama. 1997 May 14;277(18):1445-51. [DOI:10.1001/jama.1997.03540420041027] [PMID]
8. Kamalian N, Ensani F. Study On Evaluation Relation Between Pathologic Finding With Serum Tpsa Of Patients With Urinary Obstructive Symptoms In Shariati Hospital (1998-2000).
9. Mehrabibahar M. Comparison of free PSA serum and total PSA serum and ratio of these two factors in patients with prostate adenocarcinoma and benign prostate hyperplasia 3 years. 2016.
10. Jamali M, Moghadam K. Statistical study and review of prostatic latent carcinoma. Tehran University Medical Journal TUMS Publications. 1996 Mar 10;54(1):37-41.
11. Baghinia M, Shariatzade M, Baghinia N.Evaluate the relationship between prostate specific antigen (PSA) and calciun in men with prostate cancer and benign prostate hyperplasia.Arak Medical University Journal. 2014; 16(10);19-26.
12. Yazdani M, Baradaran A, Kabiri M, Koushki AM. Relation between Serum Level of Total PSA and Free PSA/Total PSA Ratio with Grade of Prostate Cancer. Journal of Isfahan Medical School. 2013 Oct 15;31(249).
13. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, Marberger M. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology. 1999 Sep 1;54(3):517-22. [DOI:10.1016/S0090-4295(99)00153-3]
14. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology. 1999 Aug 1;54(2):220-4. [DOI:10.1016/S0090-4295(99)00185-5]
15. Horiguchi A, Nakashima J, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Marumo K, Murai M. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. The Prostate. 2003 Jun 15;56(1):23-9. [DOI:10.1002/pros.10239] [PMID]
16. Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL. The ability of prostate‐specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. Bju international. 2012 Jul 1;110(1):36-42. [DOI:10.1111/j.1464-410X.2011.10681.x] [PMID]
17. Sfoungaristos S, Perimenis P. PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer. Canadian Urological Association Journal. 2012 Feb;6(1):46. [DOI:10.5489/cuaj.329]
18. Ghoreishi A, Demographic and histotopographic Specifications of solid cancers in patients referred to medical centers in South Khorasan province from 2011 to 2016.
19. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison's Principles of Internal Medicine, (Vol. 1 & Vol. 2): McGraw Hill Professional; 2018.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Research in Urology

Designed & Developed by : Yektaweb